- About MEDx
- Technology Centers
- Pharma Solutions
-
CDx/IVD Products
IHC-Based AssaysPCR-Based AssaysNGS-Based AssaysMore AssaysCustomized Assays - Clinical Testing
- Quality Systems
- Events
- Contact Us
c-MET is a proto-oncogene that encodes a transmembrane receptor for Hepatocyte Growth Factor (HGF) and has Tyrosine Kinase (TKs) activity. Abnormal c-MET is related to the occurrence and development of various tumors. The detection of abnormal c-MET mainly includes the following methods: (1) Immunohistochemistry (IHC) to detect c-MET overexpression, (2) Fluorescence In Situ Hybridization (FISH) to detect MET amplification, and (3) Next Generation Sequencing (NGS)/PCR to detect MET exon 14 skipping mutations or activating mutations. MEDx Translational Medicine provides pharmaceutical companies with complete solutions, including c-MET IHC, FISH, NGS, PCR, and multi-dimensional comprehensive analysis of c-MET abnormalities.
Digital PCR
Low testing cost, mature technology, and easy clinical development
Pan-solid tumors, mainly lung cancer
If you have any of the following needs, feel free to contact us or email us at inquiry@MEDxTMC.net . We will reply within 24 hours.
1. Customized or bulk orders of IVD/CDx products.
2. Get a quote for IVD/CDx products
3. Become our distributor
4. Get customized pharmaceutical service solutions
5.Learn more about our technology and R&D
